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Purpose of the study
The risk of opportunistic infections and inefficient
immune reconstitution in advanced naive HIV+ patients
starting HAART are critical issues in the management of
HIV infection. We studied the effects of IL-2 adjuvant ther-
apy in favoring a rapid CD4 cell rescue, shortening the
time frame at highest risk of HIV-related clinical events in
patients with severe immune impairment.
Methods
After 2 weeks of HAART, 73 HAART-naive patients with
baseline CD4 cells <200/μL were randomized to receive
IL-2+HAART (n = 33) or to continue ongoing HAART (n =
40). Three cycles of IL-2 were administered (one cycle: 3 ×
106 IU QD sc at days 1–5 and 8–12), for an overall dura-
tion of 3 months. Patients were followed-up over 18
months. Patients failing to show a sustained CD4 recovery
of >30% from baseline after 6 months (IL-2 non-respond-
ers, IL-2NR) received three further IL-2 cycles.
Summary of results
At baseline, IL-2 and HAART-control patients were com-
parable in terms of median CD4 counts (61/μL and 48/
μL, respectively, p = 0.23) and prevalence of patients with
AIDS-defining conditions (HAART-controls: 27; IL-2
patients: 15, p = 0.1). Rapid HIV-RNA decrease with no
rebounds was observed in both IL-2 and HAART-patients.
Major results are shown in Table 1. Compared to HAART-
controls, IL-2 resulted in a more significant and rapid CD4
rescue after 3 months (p = 0.01). However, response to IL-
2 was not equally persistent among patients: IL-2R dis-
played a higher and more sustained CD4 recovery up to
month 18 respect to IL-2NR (p = 0.01) and controls (p =
0.04). Three additional cycles in IL-2NR did not result in
any further significant CD4 recovery. During study period,
AIDS-defining events were diagnosed in six (15%)
HAART-controls and in one (3%) IL-2+HAART patient (p
= 0.06).
Conclusion
In advanced naïve patients, IL-2 adjuvant therapy is effica-
cious in inducing a rapid and significant CD4 reconstitu-
tion, in most cases sustained up to 18 months. The
finding of a reduced prevalence of patients developing
AIDS-defining conditions suggests a possible efficacy in
functional immune enhancement which may translate
into earlier clinical benefit.
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Group Median CD4/μL change from 
BL (T3 mths)
Median CD4/μL change from 
BL (T6 mths)
Median CD4/μL change from 
BL (T18 mths)
IL-2+HAART patients (n = 33) +145 +59 +107
IL-2R (n = 23/33) +161 +91 +135
IL-2 NR (n = 10/33) +95 +28 +74
HAART controls (n = 40) +20 +59 +97Page 2 of 2
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